

N A Mark Estes Iii

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5010679/publications.pdf>

Version: 2024-02-01

100
papers

8,629
citations

236925

25
h-index

82547

72
g-index

101
all docs

101
docs citations

101
times ranked

7086
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. <i>New England Journal of Medicine</i> , 2009, 361, 1329-1338.	27.0	2,716
2	Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. <i>New England Journal of Medicine</i> , 2004, 350, 2151-2158.	27.0	1,840
3	Reduction in Inappropriate Therapy and Mortality through ICD Programming. <i>New England Journal of Medicine</i> , 2012, 367, 2275-2283.	27.0	1,186
4	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. <i>Heart Rhythm</i> , 2019, 16, e301-e372.	0.7	494
5	Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. <i>European Heart Journal</i> , 2015, 36, 1735-1743.	2.2	236
6	Task Force 7: Arrhythmias. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1354-1363.	2.8	192
7	Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2017, 136, 2420-2436.	1.6	183
8	Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. <i>European Heart Journal</i> , 2015, 36, ehv162.	2.2	171
9	Ventricular Arrhythmias in the North American Multidisciplinary Study of ARVC. <i>Journal of the American College of Cardiology</i> , 2014, 64, 119-125.	2.8	156
10	The State of the Art. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1778-1810.	3.0	154
11	Selective Activation of the K ⁺ ATP Channel Is a Mechanism by Which Sudden Death Is Produced by Low-Energy Chest-Wall Impact (Commotio Cordis). <i>Circulation</i> , 1999, 100, 413-418.	1.6	135
12	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. <i>Heart Rhythm</i> , 2019, 16, e373-e407.	0.7	135
13	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects. <i>Circulation</i> , 2015, 132, e315-25.	1.6	114
14	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. <i>Circulation</i> , 2017, 135, 2310-2312.	1.6	107
15	Commotio Cordis? Sudden Cardiac Death with Chest Wall Impact. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 115-122.	1.7	82
16	Incidence and Significance of Pacemaker and Implantable Cardioverter-Defibrillator Lead Masses Discovered during Transesophageal Echocardiography. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 679-683.	1.2	68
17	Predicting and Preventing Sudden Cardiac Death. <i>Circulation</i> , 2011, 124, 651-656.	1.6	55
18	Predictors and Clinical Impact of Atrial Fibrillation After Pacemaker Implantation in Elderly Patients Treated with Dual Chamber Versus Ventricular Pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 2000-2007.	1.2	44

#	ARTICLE	IF	CITATIONS
19	Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 125, 210-214.	1.6	39
20	Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: Findings from the North American ARVC Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 555-562.	1.7	37
21	Atrial Fibrillation in Athletes. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 921-928.	3.2	35
22	Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2017, 119, 1862-1865.	1.6	34
23	Cell Membrane Stretch and Chest Blow-Induced Ventricular Fibrillation: Commotio Cordis. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 1304-1309.	1.7	33
24	The Disconnect Between the Guidelines, the Appropriate Use Criteria, and Reimbursement Coverage Decisions. <i>Journal of the American College of Cardiology</i> , 2014, 63, 12-14.	2.8	28
25	Impact of Lifestyle Modification on Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 125, 289-297.	1.6	27
26	Prediction and Prevention of Sudden Cardiac Death. <i>Cardiac Electrophysiology Clinics</i> , 2017, 9, 631-638.	1.7	26
27	Apical hypertrophic cardiomyopathy presenting with sustained monomorphic ventricular tachycardia and electrocardiographic changes simulating coronary artery disease and left ventricular aneurysm. <i>Clinical Cardiology</i> , 1990, 13, 885-887.	1.8	25
28	Preparticipation Athletic Screening Including an Electrocardiogram: An Unproven Strategy for Prevention of Sudden Cardiac Death in the Athlete. <i>Progress in Cardiovascular Diseases</i> , 2012, 54, 451-454.	3.1	24
29	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	1.5	24
30	Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2019, 123, 1859-1862.	1.6	24
31	Pacemakers and Exercise Current Status, Future Developments and Practical Implications of Physiological Pacemakers. <i>Sports Medicine</i> , 1989, 8, 1-8.	6.5	22
32	Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008123.	4.8	21
33	Use of antiarrhythmics and implantable cardioverter-defibrillators in congestive heart failure. <i>American Journal of Cardiology</i> , 2003, 91, 45-52.	1.6	15
34	Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field?. <i>American Journal of Cardiology</i> , 2018, 121, 1008-1010.	1.6	13
35	Cardiac Safety of Electrical Stun Guns: Letting Science and Reason Advance the Debate. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2008, 31, 395-397.	1.2	11
36	Agreement Between ICU Clinicians and Electrophysiology Cardiologists on the Decision to Initiate a QTc Interval Prolonging Medication in Critically Ill Patients with Potential Risk Factors for Torsade de Pointes: A Comparative, Case-Based Evaluation. <i>Pharmacotherapy</i> , 2013, 33, 589-597.	2.6	10

#	ARTICLE	IF	CITATIONS
37	Advances in Sudden Death Prevention: The Emerging Role of a Fully Subcutaneous Defibrillator. <i>American Journal of Medicine</i> , 2014, 127, 188-194.	1.5	10
38	Evaluation and Management of Heart Rhythm Disturbances Due to Cardiac Sarcoidosis. <i>Heart Lung and Circulation</i> , 2014, 23, 1100-1109.	0.4	9
39	Inappropriate Shocks and Elevation of Defibrillation Thresholds in a Patient with Automatic Defibrillator Patch Silastic Erosion and Titanium Mesh Fraying. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991, 14, 1452-1455.	1.2	6
40	Priority plan for invasive cardiac electrophysiology procedures during the coronavirus disease 2019 (COVID-19) pandemic. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1255-1258.	1.7	6
41	Curing atrial fibrillation: Two decades of progress. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2007, 20, 127-131.	1.3	5
42	Is it Time for a New Approach to Implantable Cardioverter-Defibrillator Replacement?—. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2395-2397.	2.8	5
43	Advances in the Prevention and Treatment of Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 103-104.	3.1	5
44	Primary prevention of sudden death with the implantable cardioverter defibrillator: bridging the evidence gap. <i>European Heart Journal</i> , 2020, 41, 3448-3450.	2.2	5
45	Stroke Risk Stratification in Atrial Fibrillation: Bridging the Evidence Gaps. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 271-273.	1.7	4
46	Trends and Implications of DF-4 Implantable Cardioverter-Defibrillator Lead Adoption in the United States of America. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007134.	4.8	4
47	Impact of Diabetes Mellitus on Mortality and Hospitalization in Patients With Mild-to-Moderate Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 552-558.	3.2	4
48	Impact of an Automated Best Practice Alert on Sex and Race Disparities in Implantable Cardioverter-Defibrillator Therapy. <i>Journal of the American Heart Association</i> , 2022, 11, e023669.	3.7	4
49	Automated External Defibrillators in the Public Domain. <i>Circulation</i> , 2005, 112, e349-51.	1.6	3
50	Ablation of Atrial Flutter in Severe Pulmonary Hypertension: Pushing the Outside of the Envelope. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1191-1192.	1.7	3
51	Impact of generator replacement on the risk of Fidelis lead fracture. <i>Heart Rhythm</i> , 2016, 13, 1618-1623.	0.7	3
52	His bundle pacing. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 323-334.	1.3	3
53	Mobile cardiac monitoring during the COVID-19 pandemic: Necessity is the mother of invention. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2812-2813.	1.7	3
54	Inverse association of mortality and body mass index in patients with left ventricular systolic dysfunction of both ischemic and <sc>non-ischemic</sc> etiologies. <i>Clinical Cardiology</i> , 2021, 44, 495-500.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Ventricular pacing and myocardial function in patient with congenital heart block. Journal of Cardiovascular Electrophysiology, 2021, 32, 2684-2689.	1.7	3
56	Examining Achillesâ€™ Heel. JACC: Cardiovascular Imaging, 2014, 7, 1249-1250.	5.3	2
57	Documentation of shared decision making around primary prevention defibrillator implantations. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 100-109.	1.2	2
58	Improving Outcomes in Patients With Atrial Fibrillation and Hypertension. JAMA - Journal of the American Medical Association, 2020, 323, 221.	7.4	2
59	Ablation of Atrial Fibrillation in Hypertrophic Cardiomyopathy: Semper Discere (Always Learning). Journal of the American Heart Association, 2021, 10, e019876.	3.7	2
60	Outcomes of Blacks Versus Whites with Cardiomyopathy. American Journal of Cardiology, 2021, 148, 151-156.	1.6	2
61	Should Preparticipation Cardiovascular Screening of Athletes Include ECG? No: There Is Not Enough Evidence to Support Including ECG in the Preparticipation Sports Evaluation. American Family Physician, 2015, 92, 343-4.	0.1	2
62	Molecular biology of human arrhythmias: implications for the clinical electrophysiologist. , 1998, 2, 321-324.		1
63	Assessment of risk for sudden cardiac death. Current Problems in Cardiology, 2002, 27, 246-266.	2.4	1
64	Interdisciplinary strategies for arrhythmia program development: measuring quality, performance, and outcomes. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 91-99.	1.3	1
65	Following leads to improve patient outcomes: Itâ€™s about time. Heart Rhythm, 2014, 11, 2163-2164.	0.7	1
66	Left Atrial Appendage Closure for Stroke Prevention in AF. Journal of the American College of Cardiology, 2015, 66, 2740-2742.	2.8	1
67	Clinical Outcomes of Patients Who Received the Subcutaneous Implantable Cardioverter Defibrillator. JAMA Cardiology, 2016, 1, 861.	6.1	1
68	Response to Letter Regarding Article, "Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement" Circulation, 2016, 133, e437-8.	1.6	1
69	Defibrillation threshold testing in hypertrophic cardiomyopathy: As SIMPLE as possible but not simpler. Heart Rhythm, 2018, 15, 393-394.	0.7	1
70	Prediction and Prevention of Sudden Death in the Brugada Syndrome. American Journal of Cardiology, 2019, 124, 1797-1802.	1.6	1
71	Exercise and Athletic Activity in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 173-182.	1.7	1
72	Cardiac Magnetic Resonance Imaging in Nonischemic Cardiomyopathy. Circulation, 2021, 143, 1374-1376.	1.6	1

#	ARTICLE	IF	CITATIONS
73	A Blueprint for Productive Maintenance of Certification, But Is the American Board of Internal Medicine up to the Challenge?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006696.	2.2	1
74	Predictors of Hospital Admissions for Ventricular Arrhythmia or Cardiac Arrest in Patients With Cardiomyopathy. <i>American Journal of Cardiology</i> , 2022, 171, 127-131.	1.6	1
75	Discrimination When Dual-Chamber Termination Fails: A New Paradigm for ICDs?. <i>Journal of Cardiovascular Electrophysiology</i> , 2006, 17, 702-704.	1.7	0
76	Clinical. <i>Heart Rhythm</i> , 2009, 6, 1542.	0.7	0
77	EP News: Clinical. <i>Heart Rhythm</i> , 2013, 10, 1247.	0.7	0
78	Mayo Clinic Electrophysiology Manual Asirvatham Samuel J., Ed. 711 pages. Oxford, UK: Oxford University Press, 2013. \$147.98. ISBN:13 978-0199941193. <i>Circulation</i> , 2014, 129, 1992-1993.	1.6	0
79	Cardiac Resynchronization Therapy for Mild Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 701-702.	4.1	0
80	In Reply Atrial Fibrillation: Interatrial Block May Be an Underdiagnosed and Easily Recognizable Risk Factor. <i>Mayo Clinic Proceedings</i> , 2017, 92, 682.	3.0	0
81	Sudden Cardiac Death: Contemporary Challenges. <i>Cardiac Electrophysiology Clinics</i> , 2017, 9, xvii-xviii.	1.7	0
82	Class IC antiarrhythmic agents in structural heart disease: Is nothing CAST in stone?. <i>Heart Rhythm</i> , 2018, 15, 164-165.	0.7	0
83	Implications of Neurological Status on Defibrillator Therapy and Long-Term Mortality of Sudden Cardiac Arrest Survivors. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 843-850.	3.2	0
84	In reply Atrial Fibrillation and Morbidity and Mortality in Stress-Induced Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2148-2149.	3.0	0
85	MY APPROACH to Commotio Cordis. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 248.	4.9	0
86	Improving outcomes after left atrial appendage closure. <i>Heart Rhythm</i> , 2020, 17, 734-735.	0.7	0
87	Risk Factor Modification for Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1288-1290.	3.2	0
88	Response by Alyesh et al to Letter Regarding Article, "A Blueprint for Productive Maintenance of Certification, but Is the American Board of Internal Medicine up to the Challenge?" <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007961.	2.2	0
89	EP News Clinical November 2021. <i>Heart Rhythm</i> , 2021, . .	0.7	0
90	Atrial Resynchronization Therapy: An Emerging Potential to Advance Physiologic Pacing?. <i>Heart Rhythm</i> , 2021, . .	0.7	0

#	ARTICLE	IF	CITATIONS
91	EP News Clinical February 2022. Heart Rhythm, 2022, , .	0.7	0
92	EP News Clinical April 3, 2022. Heart Rhythm, 2022, , .	0.7	0
93	Electroanatomical Mapping of a Left-Sided Atrial Tachycardia. , 0, , 59-60.		0
94	Scar-Related Intraatrial Reentrant Tachycardia. , 0, , 99-101.		0
95	Right Ventricular Outflow Tachycardia. , 0, , 163-164.		0
96	Voltage Mapping of the Right Ventricle in Arrhythmogenic Right Ventricular Dysplasia. , 0, , 189-190.		0
97	Substrate Modification in Hemodynamically Unstable Infarct-Related Ventricular Tachycardia. , 0, , 229-231.		0
98	EP News Clinical May 2022. Heart Rhythm, 2022, , .	0.7	0
99	EP News Clinical June 2022. Heart Rhythm, 2022, , .	0.7	0
100	EP News Clinical July 2022. Heart Rhythm, 2022, , .	0.7	0